Results 121 to 130 of about 70,073 (274)

Mausolate Complexes of the Alkaline Earth Metals

ChemistryEurope, Volume 4, Issue 3, March 2026.
Reliable chelation of Ra2+ for radionuclide therapy has long been a challenge, and the capacious and rigid mausolate ligand may offer a promising approach. We describe herein mausolate complexes with the chemically similar Ba2+, and other group 2 dications, including the introduction of functionalized derivatives. The rapid uptake of alkaline earth (Ae)
Jack F. Smart, Liam D. N. Krueckl, R. Quinn Schmidt, Leah Gajecki, Lindsey E. K. Frederiksen, Allen G. Oliver, David J. Berg, J. Scott McIndoe   +7 more
wiley   +1 more source

A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!

International Journal of Biological Sciences, 2011
Prostate cancer is the second leading cause of cancer-related death in American men. Although most prostate cancers are initially androgen-dependent and respond to androgen ablation therapy, majority of them eventually relapse and progress into incurable
Zhiyong Guo, Yun Qiu
doaj  

The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
The acyl‐CoA synthetase long‐chain (ACSL) family consists of five members, which exhibit a synergistic effect in promoting tumour lipid metabolism for energy supply. Specifically, ACSL3 and ACSL4 have antagonistic effects on the mechanisms related to ferroptosis in tumour cells.
Haocai Li, Weijian Wang, Juncheng Zhan, Yuxiang Xiao, Xiaoping Chen, Chen Su, Peng Zhu   +6 more
wiley   +1 more source

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Nature Medicine, 2022
V. Narayan, J. Barber-Rotenberg, In-Young Jung, S. Lacey, A. Rech, M. Davis, W. Hwang, P. Lal, E. Carpenter, S. Maude, G. Plesa, N. Vapiwala, A. Chew, Michael Moniak, R. Sebro, M. Farwell, A. Marshall, J. Gilmore, Lester Lledo, Karen Dengel, S. Church, Tyler D. Hether, Junnnan Xu, M. Gohil, Thomas H. Buckingham, S. Yee, V. Gonzalez, I. Kulikovskaya, Fang Chen, Lifeng Tian, Kyle Tien, W. Gladney, Christopher L. Nobles, H. Raymond, Diane Mary Elizabeth Holly Jonathan Samantha Sophia Juli Frazee Truran Veloso McConville Aguedelo Hower Ngo, D. Frazee, Mary Truran, E. Veloso, Holly McConville, Jonathan Aguedelo, S. Hower, Sophia Ngo, J. Jadlowsky, J. Melenhorst, A. Roche, J. Everett, Minnal Gupta, Farzana Nazimuddin, C. Bartoszek, Natalka Koterba, R. Reynolds, F. Ellington, Christopher C. Kloss, Jihyun Lee, Yangbing Zhao, J. Scholler, J. Riley, Christina Bailey, A. White, Briana M. Hudson, Pearl S Chang, M. Maus, B. Levine, E. Hexner, D. Siegel, F. Bushman, C. June, J. Fraietta, N. Haas   +68 more
semanticscholar   +1 more source

Artificial Intelligence and Prostate–Breast Cancer Biology: Recent Advances in Treatments and Perspectives — A Comprehensive Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims The therapeutic limitations of conventional cancer treatment currently deployed are driving the development and creation of new nano‐drugs. Prostate cancer (PCa) is a prevalent clinical problem in older men with a significant global incidence, with 1.5 million cases reported in 2022.
Russell B. O. Ouma, Silas M. Ngari, Joshua K. Kibet   +2 more
wiley   +1 more source

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials

Discover Oncology
Radioligand therapy is a targeted cancer treatment modality in which radioisotopes are utilized in the delivery of radiation at targeted cancer cells, with the goal of sparing normal cells.
Alexander Konopnicki, Michael Zaliznyak, Mathews Roy, Bagi Jana   +3 more
doaj   +1 more source

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

The Lancet, 2011
K. Fizazi, M. Carducci, Matthew R. Smith, R. Damião, Janet E Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, Huei Wang, Q. Jiang, Sylvia Tadros, R. Dansey, C. Goessl   +13 more
semanticscholar   +1 more source

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research, 2008
J. D. de Bono, H. Scher, R. Montgomery, C. Parker, M. Miller, H. Tissing, G. Doyle, L. Terstappen, K. Pienta, D. Raghavan   +9 more
semanticscholar   +1 more source

Apalutamide‐Induced Hypothyroidism Associated With Increased Thyroid Hormone Clearance in Metastatic Prostate Cancer Patient: A Case Report

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Apalutamide (APA) is an androgen receptor signaling inhibitor widely used for metastatic hormone‐sensitive prostate cancer (mHSPC), though it can induce hypothyroidism. We report a severe case of APA‐induced hypothyroidism in a patient with a history of total thyroidectomy.
Jun Furumido, Akihiro Yamashita, Ryo Kato, Kanta Hori   +3 more
wiley   +1 more source

Targeting GRP78 and the Proteostasis Network to Break the Therapeutic Ceiling in Neuroendocrine Prostate Cancer

iNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT HSPA5 (also known as GRP78/BiP) is a master regulator of the endoplasmic reticulum (ER) stress response and a key node in the proteostasis network. In neuroendocrine prostate cancer (NEPC), an aggressive, therapy‐refractory lineage that emerges under pressure from androgen receptor (AR) directed therapies, GRP78 is upregulated and co‐opted to ...
Amos Olalekan Akinyemi, Md Rakibul Alam, Mithu Howlader, Mohammad Esfini Farahani, Lixiang Gu, Chun Li, Chripus Ngule, Kevin Fulp, Bolaji Owoyemi, Xinyi Wang, Samuel Nwadialo, Fatemeh Selani, Makumba Esoe, Obaleye Oluwafunminiyi, Zhiguo Li   +14 more
wiley   +1 more source